Regeneron (REGN) announces EMA Issues Advice on its Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. PRIM
6. META
7. SPY
8. DPZ
9. NAVN
10. NVDA

Go back to Regeneron (REGN) announces EMA Issues Advice on its Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients

Regeneron (REGN) Reports Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma

March 1, 2021 5:48 AM EST

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed results from a Phase 2 proof-of-concept trial evaluating the investigational antibody cocktail REGN1908-1909 in cat-allergic patients with mild asthma. The trial met the primary endpoint of preventing early asthma reactions (EAR, defined as a 20% decline in forced expiratory volume over one second [FEV1]). The trial also met key secondary endpoints, including improved lung function and an increased amount of cat allergen that patients could tolerate following a single dose of treatment, from as early as the first assessment conducted at week 1. The results were... More